Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Genome Studies Can Help Find Lifestyle Risks for Diseases

By Drug Discovery Trends Editor | February 16, 2016

Genome wide association studies (GWAS) scan the entire genome in order to pinpoint genetic variants associated with a particular disease. The technique is employed to identify biological pathways – the series of actions and changes that have occurred in cells and genetic material – that can be linked to the causation of a disease.

A team of researchers from the University of Bristol and Oxford University have suggested, in a paper published this week in PLOS Genetics, that a GWAS for a disease should also identify genetic variants that predict behaviors that increase the risk of the disease as well. If this is the case, GWAS may be useful places to look for potentially modifiable risk factors for disease, which could then be targeted by medics for interventions.

Professor Marcus Munafo, the study’s lead author, said: “Genome-wide association studies of lung cancer have identified genetic variants that strongly predict smoking. It is possible these genetic variants have independent effects on both smoking and lung cancer, but it seems far more likely that this variant was seen because smoking causes lung cancer.

“Genetic predictors for lifestyle are still being identified. We already know about variants that predict smoking, alcohol or caffeine use, and research is ongoing to predict things like cannabis use. As larger GWASs of disease are carried out, more of these variants which indicate the causal modifiable risk factors for disease will be identified. This will help the development of more effective and better-targeted interventions.

“These discoveries really underline how valuable the investment in genetic studies is – more so than is often thought. Genetic studies can not only identify the biological risk factors for disease, but the behavioural risk factors as well”

Source: University of Bristol


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE